Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Antimicrobial activity of Mimosa caesalpiniifolia Benth and its interaction with antibiotics against Staphylococcus aureus strains overexpressing efflux pump genes.

Silva SWC, Monção NBN, Araújo BQ, Arcanjo DDR, Ferreira JHL, Lima Neto JS, Citó AMGL, de Siqueira Júnior JP, Kaatz GW, Barreto HM.

Lett Appl Microbiol. 2019 Jul;69(1):57-63. doi: 10.1111/lam.13163. Epub 2019 May 15.

PMID:
31002429
2.

Antimicrobial activity of Phyllanthus amarus Schumach. & Thonn and inhibition of the NorA efflux pump of Staphylococcus aureus by Phyllanthin.

Braga Ribeiro AM, Sousa JN, Costa LM, Oliveira FAA, Dos Santos RC, Silva Nunes AS, da Silva WO, Marques Cordeiro PJ, de Sousa Lima Neto J, de Siqueira-Júnior JP, Kaatz GW, Barreto HM, de Oliveira AP.

Microb Pathog. 2019 May;130:242-246. doi: 10.1016/j.micpath.2019.03.012. Epub 2019 Mar 12.

PMID:
30876871
3.

2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.

Felicetti T, Cannalire R, Pietrella D, Latacz G, Lubelska A, Manfroni G, Barreca ML, Massari S, Tabarrini O, Kieć-Kononowicz K, Schindler BD, Kaatz GW, Cecchetti V, Sabatini S.

J Med Chem. 2018 Sep 13;61(17):7827-7848. doi: 10.1021/acs.jmedchem.8b00791. Epub 2018 Aug 17.

PMID:
30067360
4.

Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position.

Felicetti T, Cannalire R, Nizi MG, Tabarrini O, Massari S, Barreca ML, Manfroni G, Schindler BD, Cecchetti V, Kaatz GW, Sabatini S.

Eur J Med Chem. 2018 Jul 15;155:428-433. doi: 10.1016/j.ejmech.2018.06.013. Epub 2018 Jun 6.

PMID:
29908437
5.

Searching for Novel Inhibitors of the S. aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3-Phenyl-1,4-benzothiazine Analogues.

Felicetti T, Cannalire R, Burali MS, Massari S, Manfroni G, Barreca ML, Tabarrini O, Schindler BD, Sabatini S, Kaatz GW, Cecchetti V.

ChemMedChem. 2017 Aug 22;12(16):1293-1302. doi: 10.1002/cmdc.201700286. Epub 2017 Jul 17.

PMID:
28598572
6.

Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.

Astolfi A, Felicetti T, Iraci N, Manfroni G, Massari S, Pietrella D, Tabarrini O, Kaatz GW, Barreca ML, Sabatini S, Cecchetti V.

J Med Chem. 2017 Feb 23;60(4):1598-1604. doi: 10.1021/acs.jmedchem.6b01439. Epub 2017 Feb 8.

PMID:
28117588
7.

Improved Potency of Indole-Based NorA Efflux Pump Inhibitors: From Serendipity toward Rational Design and Development.

Buonerba F, Lepri S, Goracci L, Schindler BD, Seo SM, Kaatz GW, Cruciani G.

J Med Chem. 2017 Jan 12;60(1):517-523. doi: 10.1021/acs.jmedchem.6b01281. Epub 2016 Dec 15.

PMID:
27977195
8.

Inhibition of the NorA efflux pump of Staphylococcus aureus by synthetic riparins.

Costa LM, de Macedo EV, Oliveira FA, Ferreira JH, Gutierrez SJ, Peláez WJ, Lima FC, de Siqueira Júnior JP, Coutinho HD, Kaatz GW, de Freitas RM, Barreto HM.

J Appl Microbiol. 2016 Nov;121(5):1312-1322. doi: 10.1111/jam.13258. Epub 2016 Oct 2.

PMID:
27537678
9.

Inhibition of the NorA multi-drug transporter by oxygenated monoterpenes.

Coêlho ML, Ferreira JH, de Siqueira Júnior JP, Kaatz GW, Barreto HM, de Carvalho Melo Cavalcante AA.

Microb Pathog. 2016 Oct;99:173-177. doi: 10.1016/j.micpath.2016.08.026. Epub 2016 Aug 24.

PMID:
27565089
10.

Multidrug efflux pumps of Gram-positive bacteria.

Schindler BD, Kaatz GW.

Drug Resist Updat. 2016 Jul;27:1-13. doi: 10.1016/j.drup.2016.04.003. Epub 2016 Apr 30. Review.

PMID:
27449594
11.

The "racemic approach" in the evaluation of the enantiomeric NorA efflux pump inhibition activity of 2-phenylquinoline derivatives.

Carotti A, Ianni F, Sabatini S, Di Michele A, Sardella R, Kaatz GW, Lindner W, Cecchetti V, Natalini B.

J Pharm Biomed Anal. 2016 Sep 10;129:182-189. doi: 10.1016/j.jpba.2016.07.003. Epub 2016 Jul 4.

PMID:
27429367
12.

Indole Based Weapons to Fight Antibiotic Resistance: A Structure-Activity Relationship Study.

Lepri S, Buonerba F, Goracci L, Velilla I, Ruzziconi R, Schindler BD, Seo SM, Kaatz GW, Cruciani G.

J Med Chem. 2016 Feb 11;59(3):867-91. doi: 10.1021/acs.jmedchem.5b01219. Epub 2016 Jan 26.

PMID:
26757340
13.

A mass spectrometry-based assay for improved quantitative measurements of efflux pump inhibition.

Brown AR, Ettefagh KA, Todd D, Cole PS, Egan JM, Foil DH, Graf TN, Schindler BD, Kaatz GW, Cech NB.

PLoS One. 2015 May 11;10(5):e0124814. doi: 10.1371/journal.pone.0124814. eCollection 2015.

14.

Mutations within the mepA operator affect binding of the MepR regulatory protein and its induction by MepA substrates in Staphylococcus aureus.

Schindler BD, Seo SM, Birukou I, Brennan RG, Kaatz GW.

J Bacteriol. 2015 Mar;197(6):1104-14. doi: 10.1128/JB.02558-14. Epub 2015 Jan 12.

15.

Clonal relatedness is a predictor of spontaneous multidrug efflux pump gene overexpression in Staphylococcus aureus.

Schindler BD, Jacinto PL, Buensalido JA, Seo SM, Kaatz GW.

Int J Antimicrob Agents. 2015 May;45(5):464-70. doi: 10.1016/j.ijantimicag.2014.11.007. Epub 2014 Dec 10.

PMID:
25548027
16.

Analyses of multidrug efflux pump-like proteins encoded on the Staphylococcus aureus chromosome.

Schindler BD, Frempong-Manso E, DeMarco CE, Kosmidis C, Matta V, Seo SM, Kaatz GW.

Antimicrob Agents Chemother. 2015 Jan;59(1):747-8. doi: 10.1128/AAC.04678-14. Epub 2014 Nov 17. No abstract available.

17.

Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin Activity.

Steed ME, Hall AD, Salimnia H, Kaatz GW, Kaye KS, Rybak MJ.

Infect Dis Ther. 2013 Dec;2(2):187-200. doi: 10.1007/s40121-013-0021-7. Epub 2013 Nov 29.

18.

Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.

Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V.

Clin Ther. 2014 Oct 1;36(10):1317-33. doi: 10.1016/j.clinthera.2014.05.061. Epub 2014 Jul 10.

PMID:
25017183
19.

Structural mechanism of transcription regulation of the Staphylococcus aureus multidrug efflux operon mepRA by the MarR family repressor MepR.

Birukou I, Seo SM, Schindler BD, Kaatz GW, Brennan RG.

Nucleic Acids Res. 2014 Feb;42(4):2774-88. doi: 10.1093/nar/gkt1215. Epub 2013 Nov 28.

20.

A new plant-derived antibacterial is an inhibitor of efflux pumps in Staphylococcus aureus.

Shiu WK, Malkinson JP, Rahman MM, Curry J, Stapleton P, Gunaratnam M, Neidle S, Mushtaq S, Warner M, Livermore DM, Evangelopoulos D, Basavannacharya C, Bhakta S, Schindler BD, Seo SM, Coleman D, Kaatz GW, Gibbons S.

Int J Antimicrob Agents. 2013 Dec;42(6):513-8. doi: 10.1016/j.ijantimicag.2013.08.007. Epub 2013 Sep 16.

PMID:
24119569
21.

The molecular mechanisms of allosteric mutations impairing MepR repressor function in multidrug-resistant strains of Staphylococcus aureus.

Birukou I, Tonthat NK, Seo SM, Schindler BD, Kaatz GW, Brennan RG.

MBio. 2013 Aug 27;4(5):e00528-13. doi: 10.1128/mBio.00528-13.

22.

Functional consequences of substitution mutations in MepR, a repressor of the Staphylococcus aureus MepA multidrug efflux pump gene.

Schindler BD, Seo SM, Jacinto PL, Kumaraswami M, Birukou I, Brennan RG, Kaatz GW.

J Bacteriol. 2013 Aug;195(16):3651-62. doi: 10.1128/JB.00565-13. Epub 2013 Jun 7.

23.

Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.

Sabatini S, Gosetto F, Iraci N, Barreca ML, Massari S, Sancineto L, Manfroni G, Tabarrini O, Dimovska M, Kaatz GW, Cecchetti V.

J Med Chem. 2013 Jun 27;56(12):4975-89. doi: 10.1021/jm400262a. Epub 2013 Jun 13.

PMID:
23710549
24.

Antibacterial sesquiterpenoid derivatives from Ferula ferulaeoides.

Liu T, Osman K, Kaatz GW, Gibbons S, Mu Q.

Planta Med. 2013 May;79(8):701-6. doi: 10.1055/s-0032-1328461. Epub 2013 May 13.

PMID:
23670622
26.

Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.

Vidaillac C, Gardete S, Tewhey R, Sakoulas G, Kaatz GW, Rose WE, Tomasz A, Rybak MJ.

J Infect Dis. 2013 Jul;208(1):67-74. doi: 10.1093/infdis/jit127. Epub 2013 Mar 28.

27.

Inhibition of drug efflux pumps in Staphylococcus aureus: current status of potentiating existing antibiotics.

Schindler BD, Jacinto P, Kaatz GW.

Future Microbiol. 2013 Apr;8(4):491-507. doi: 10.2217/fmb.13.16. Review.

PMID:
23534361
28.

Mutagenesis and modeling to predict structural and functional characteristics of the Staphylococcus aureus MepA multidrug efflux pump.

Schindler BD, Patel D, Seo SM, Kaatz GW.

J Bacteriol. 2013 Feb;195(3):523-33. doi: 10.1128/JB.01679-12. Epub 2012 Nov 21.

29.

Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of Staphylococcus aureus.

Kosmidis C, Schindler BD, Jacinto PL, Patel D, Bains K, Seo SM, Kaatz GW.

Int J Antimicrob Agents. 2012 Sep;40(3):204-9. doi: 10.1016/j.ijantimicag.2012.04.014. Epub 2012 Jul 4.

PMID:
22766161
30.

Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.

Sabatini S, Gosetto F, Serritella S, Manfroni G, Tabarrini O, Iraci N, Brincat JP, Carosati E, Villarini M, Kaatz GW, Cecchetti V.

J Med Chem. 2012 Apr 12;55(7):3568-72. doi: 10.1021/jm201446h. Epub 2012 Apr 3.

PMID:
22432682
31.

Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.

Brincat JP, Broccatelli F, Sabatini S, Frosini M, Neri A, Kaatz GW, Cruciani G, Carosati E.

ACS Med Chem Lett. 2012 Jan 23;3(3):248-51. doi: 10.1021/ml200293c. eCollection 2012 Mar 8.

32.

Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus.

Patel D, Husain M, Vidaillac C, Steed ME, Rybak MJ, Seo SM, Kaatz GW.

Int J Antimicrob Agents. 2011 Nov;38(5):442-6. doi: 10.1016/j.ijantimicag.2011.06.010. Epub 2011 Aug 12.

PMID:
21840181
33.

Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.

Steed ME, Vidaillac C, Rose WE, Winterfield P, Kaatz GW, Rybak MJ.

Antimicrob Agents Chemother. 2011 Oct;55(10):4748-54. doi: 10.1128/AAC.00084-11. Epub 2011 Jul 25.

34.

Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.

Sabatini S, Gosetto F, Manfroni G, Tabarrini O, Kaatz GW, Patel D, Cecchetti V.

J Med Chem. 2011 Aug 25;54(16):5722-36. doi: 10.1021/jm200370y. Epub 2011 Aug 3.

PMID:
21751791
35.

Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition.

Ettefagh KA, Burns JT, Junio HA, Kaatz GW, Cech NB.

Planta Med. 2011 May;77(8):835-40. doi: 10.1055/s-0030-1250606. Epub 2010 Dec 14.

36.

Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus.

Brincat JP, Carosati E, Sabatini S, Manfroni G, Fravolini A, Raygada JL, Patel D, Kaatz GW, Cruciani G.

J Med Chem. 2011 Jan 13;54(1):354-65. doi: 10.1021/jm1011963. Epub 2010 Dec 8.

PMID:
21141825
37.

Ethidium bromide MIC screening for enhanced efflux pump gene expression or efflux activity in Staphylococcus aureus.

Patel D, Kosmidis C, Seo SM, Kaatz GW.

Antimicrob Agents Chemother. 2010 Dec;54(12):5070-3. doi: 10.1128/AAC.01058-10. Epub 2010 Sep 20.

38.

In silico genetic correlations of multidrug efflux pump gene expression in Staphylococcus aureus.

Kosmidis C, DeMarco CE, Frempong-Manso E, Seo SM, Kaatz GW.

Int J Antimicrob Agents. 2010 Sep;36(3):222-9. doi: 10.1016/j.ijantimicag.2010.05.015. Epub 2010 Jul 3.

PMID:
20598861
39.

From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.

Pieroni M, Dimovska M, Brincat JP, Sabatini S, Carosati E, Massari S, Kaatz GW, Fravolini A.

J Med Chem. 2010 Jun 10;53(11):4466-80. doi: 10.1021/jm1003304. Erratum in: J Med Chem. 2011 Mar 10;54(5):1537.

PMID:
20446747
40.

Treatment strategies for infective endocarditis.

Chopra T, Kaatz GW.

Expert Opin Pharmacother. 2010 Feb;11(3):345-60. doi: 10.1517/14656560903496430. Review.

PMID:
20102302
41.

Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus.

Huang V, Cheung CM, Kaatz GW, Rybak MJ.

Int J Antimicrob Agents. 2010 Jan;35(1):25-9. doi: 10.1016/j.ijantimicag.2009.08.020. Epub 2009 Nov 8.

PMID:
19900792
42.

Structural and biochemical characterization of MepR, a multidrug binding transcription regulator of the Staphylococcus aureus multidrug efflux pump MepA.

Kumaraswami M, Schuman JT, Seo SM, Kaatz GW, Brennan RG.

Nucleic Acids Res. 2009 Mar;37(4):1211-24. doi: 10.1093/nar/gkn1046. Epub 2009 Jan 7.

43.

Inability of a reserpine-based screen to identify strains overexpressing efflux pump genes in clinical isolates of Staphylococcus aureus.

Frempong-Manso E, Raygada JL, DeMarco CE, Seo SM, Kaatz GW.

Int J Antimicrob Agents. 2009 Apr;33(4):360-3. doi: 10.1016/j.ijantimicag.2008.10.016. Epub 2008 Dec 21.

PMID:
19097759
44.

Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.

Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ.

Antimicrob Agents Chemother. 2009 Feb;53(2):805-7. doi: 10.1128/AAC.01009-08. Epub 2008 Nov 17.

45.

Multidrug efflux pump overexpression in Staphylococcus aureus after single and multiple in vitro exposures to biocides and dyes.

Huet AA, Raygada JL, Mendiratta K, Seo SM, Kaatz GW.

Microbiology. 2008 Oct;154(Pt 10):3144-53. doi: 10.1099/mic.0.2008/021188-0.

PMID:
18832320
46.

Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus.

Leonard SN, Kaatz GW, Rucker LR, Rybak MJ.

J Antimicrob Chemother. 2008 Dec;62(6):1305-10. doi: 10.1093/jac/dkn379. Epub 2008 Sep 18.

PMID:
18801920
47.

From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump.

Sabatini S, Kaatz GW, Rossolini GM, Brandini D, Fravolini A.

J Med Chem. 2008 Jul 24;51(14):4321-30. doi: 10.1021/jm701623q. Epub 2008 Jun 25.

PMID:
18578473
48.

Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides.

Chérigo L, Pereda-Miranda R, Fragoso-Serrano M, Jacobo-Herrera N, Kaatz GW, Gibbons S.

J Nat Prod. 2008 Jun;71(6):1037-45. doi: 10.1021/np800148w. Epub 2008 May 24.

PMID:
18500841
49.

Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.

German N, Wei P, Kaatz GW, Kerns RJ.

Eur J Med Chem. 2008 Nov;43(11):2453-63. doi: 10.1016/j.ejmech.2008.01.042. Epub 2008 Feb 8.

PMID:
18358571
50.

Teicoplanin pharmacodynamics in reference to the accessory gene regulator (agr) in Staphylococcus aureus using an in vitro pharmacodynamic model.

Rose WE, Kaatz GW, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2008 May;61(5):1099-102. doi: 10.1093/jac/dkn037. Epub 2008 Feb 8.

PMID:
18263568

Supplemental Content

Loading ...
Support Center